Project Details
Description
PREVAIL IV (Q5) Double-Blind Randomized Two-Phase Placebo Controlled Phase II Trial of GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus and Safety in Male Ebola Survivors with Evidence of Ebola Virus Persistence in Semen
| Status | Finished |
|---|---|
| Effective start/end date | 8/13/16 → 9/25/21 |
Funding
- LEIDOS BIOMEDICAL RESEARCH, INC.
- NATIONAL INSTITUTES OF HEALTH (NIH)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.